What BONESUPPORT does

BONESUPPORT is a Swedish orthobiologics company that develops and commercializes CERAMENT, a proprietary injectable bioceramic bone graft substitute platform, founded in 2000 and headquartered in Lund, Sweden. The company is publicly listed on Nasdaq Stockholm (BONEX) and operates wholly-owned sales subsidiaries across Europe, the United States, and Switzerland, with a distribution partnership covering India. Its products address bone voids and bone infections caused by trauma, infection, disease, or related surgery across use cases including chronic osteomyelitis, fracture-related infection, diabetic foot osteomyelitis, open fractures, periprosthetic joint infection, and benign bone tumors. Hospital customers include Apollo Hospitals, King's College Hospital London, Oxford University Hospital, Manchester University Hospital, Charité Berlin, and HCA Florida Kendall.

The CERAMENT platform is built on a patented biphasic calcium sulphate/hydroxyapatite composition that remodels to host bone in six to twelve months. The product portfolio consists of four SKUs: CERAMENT BONE VOID FILLER (osteoconductive only), CERAMENT G (gentamicin-eluting for broad-spectrum infection coverage), CERAMENT V (vancomycin-eluting for MRSA/MRSE infections), and the CERAMENT Bead Tray accessory for bead delivery. CERAMENT G holds FDA 510(k) clearance as the first and only product indicated to reduce occurrence and recurrence of bone infection in open fractures; CERAMENT V has received FDA Breakthrough Device designation and is currently progressing through the De Novo pathway. Reported clinical outcomes include a 94% infection eradication rate in chronic osteomyelitis (100 patients, 6.05-year average follow-up), 87.5% five-year survival versus 44.9% standard treatment in diabetic foot osteomyelitis, and a 3.7% deep infection rate versus 14.5% standard of care in Gustilo-Anderson IIIB open fractures.

BONESUPPORT generates revenue through direct B2B sales of medical devices to hospitals and orthopaedic surgeons, with field sales teams covering DACH, BeNeLux, UK & Ireland, the Nordics, Iberia, and the United States, supported by KOL-led clinical training programs and a channel partner (Apollo Hospitals) for India. North America represents approximately 75% of total sales, with Europe (EUROW) contributing the balance plus a small initial contribution from India. FY2025 revenue was SEK 1,175 million (up from SEK 899M in 2024 and SEK 591M in 2023), gross margin was 92.6-92.9%, and EBITDA was positive. The company has 101-250 employees and is led by CEO Torbjörn Sköld (effective September 2025) and CFO Håkan Johansson, with Dr. Michael Diefenbeck as Chief Medical Officer. Recent strategic moves include the India launch (May 2026), CMS NTAP approval and proposed improved reimbursement for CERAMENT G in the US, the SOLARIO study readout, and a SEK 100 million share buyback program completed in June 2026.

Name

BONESUPPORT

Legal name

BONE SUPPORT AB

Website

https://bonesupport.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

101–250 employees

Short description

BONESUPPORT is a Swedish orthobiologics company that develops and commercializes the CERAMENT injectable bioceramic bone graft substitute platform. It serves hospitals and orthopaedic surgeons globally, with North America representing approximately 75% of revenue and a new India entry via Apollo Hospitals.

Ownership category

akta.pro rank

Product category

Orthobiologic Bone Graft Substitutes

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Orthobiologic bone grafts
• Injectable bioceramic substitutes
• Drug-eluting bone void filler
• Antibiotic bone graft substitute
• Calcium sulphate hydroxyapatite

Headquarters

HQ city

Lund

HQ country

Sweden

HQ region

Europe

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Product Sales: BONESUPPORT generates revenue primarily through the sale of its CERAMENT bone graft substitute products. Products include CERAMENT BONE VOID FILLER (standard), CERAMENT G (gentamicin-eluting), CERAMENT V (vancomycin-eluting), and CERAMENT Bead Tray. Sales are direct to hospitals and healthcare providers through field sales teams.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

BONESUPPORT develops, manufactures, and commercializes the CERAMENT platform of injectable radiopaque osteoconductive bioceramic bone graft substitutes that remodel to host bone in six to twelve months. The product range includes CERAMENT BONE VOID FILLER for bone void filling, CERAMENT G (gentamicin-eluting) and CERAMENT V (vancomycin-eluting) antibiotic-eluting variants for bone infection management, and the CERAMENT Bead Tray accessory for bead preparation.

Product overview

BONESUPPORT is a Scandinavian orthobiologics company that has developed CERAMENT®, a proprietary technology platform of radiopaque injectable osteoconductive and drug-eluting bioceramic products. The product portfolio consists of four main offerings: CERAMENT® BONE VOID FILLER (core bone void filler without antibiotic), CERAMENT® G (gentamicin-eluting antibiotic bone graft), CERAMENT® V (vancomycin-eluting antibiotic bone graft), and CERAMENT® Bead Tray (accessory for bead delivery). All products remodel to host bone in six to twelve months. The platform enables treatment of bone defects caused by trauma, infection, disease, or related surgery. The antibiotic-eluting products (G and V) combine infection control with bone regeneration in single-stage surgical approaches.

Differentiator

Problem solved

Functional benefit

Brands

• CERAMENT: Innovative range of radiopaque injectable osteoconductive and drug-eluting bioceramic products for bone graft substitutes that remodel to host bone in six to twelve months.

Products and services

• CERAMENT BONE VOID FILLER Radiopaque injectable osteoconductive bioceramic bone graft substitute for filling bone voids and defects, backed by RCT and PROMS data showing bone remodeling outcomes equivalent to autograft. Used for trauma cases at low risk of infection.
• CERAMENT G Antibiotic-eluting bone graft substitute releasing gentamicin locally. Combines infection control with bone regeneration in single-stage treatment. FDA 510(k) cleared for reducing occurrence and recurrence of bone infection in open fractures. Used for high-risk infection cases, diabetic foot complications, chronic osteomyelitis, and fracture-related infections.
• CERAMENT V Antibiotic-eluting bone graft substitute releasing vancomycin locally. Designed primarily for bone infections caused by Methicillin-Resistant Staphylococcus aureus (MRSA) or Methicillin-Resistant Staphylococcus epidermidis (MRSE). FDA submission filed for bone infection indication.
• CERAMENT Bead Tray Optional delivery device accessory for preparing and delivering CERAMENT as pre-hardened beads, particularly useful for bone cysts prone to producing large volumes of fluid such as aneurysmal bone cysts.

Quantifiable outcome

• 94% infection eradication rate in chronic osteomyelitis (100 patients, avg 6.05 year follow-up)
• +5 more outcomes

Named customers6 records

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Apollo HospitalscoreChannel Partner/ Reseller/ Distributor · 7 May 2026Apollo Hospitals introduced CERAMENT G in India as the first advanced antibiotic-eluting bone graft substitute for treating diabetic foot complications and complex bone infections. India has over 89 million people living with diabetes. The partnership includes clinical training programs led by Prof. Venu Kavarthapu from King's College Hospital London to deploy the technology across Apollo's multidisciplinary orthopaedic and vascular teams.
• King's College Hospital LondoncoreStrategic or Co-development PartnerProf. Venu Kavarthapu from King's College Hospital London led clinical training for Apollo Hospitals India on CERAMENT G deployment. KCL serves as a key opinion leader and training partner for BONESUPPORT's international expansion.
• European Bone & Joint Infection Society (EBJIS)coreStrategic or Co-development PartnerEBJIS collaborated on the SOLARIO study - a multi-centre randomized controlled trial involving 500 patients investigating whether systemic antibiotic duration can be reduced to less than 7 days when combined with local antibiotics. BONESUPPORT co-developed educational content and webinars with EBJIS on bone infection management.
• DNB Carnegie Investment Bank ABminorOthersDNB Carnegie Investment Bank AB manages share buyback programs on behalf of BONESUPPORT in accordance with MAR and Safe Harbour Regulation. Makes independent trading decisions regarding timing of acquisitions.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Stryker: Global orthopedic and medical device leader with a biologics portfolio (including bone graft substitutes) sold through much larger reconstructive and trauma sales forces; competing at the hospital procurement level across BONESUPPORT's indications.
• NuVasive (now Globus Medical): Spine and orthopedic device company with orthobiologics offerings (including synthetic and DBM bone grafts) used in spine and trauma procedures — overlapping technology and surgical specialties.
• Medtronic: Largest medtech incumbent with orthopedic and biologics offerings (including spine bone grafts) and global hospital sales coverage — addresses the same trauma, spine and reconstructive indications with broader portfolios.
• Zimmer Biomet: Major orthopedic reconstruction and biologics player with bone void fillers and regenerative products used in trauma, joint reconstruction and revision arthroplasty — overlapping indications with CERAMENT.
• Smith+Nephew: Diversified medical device company with an orthopedics franchise including bone grafts, regenerative technologies and trauma products sold to the same hospital and surgeon customer base.

Direct peers

• Integra LifeSciences: US-listed orthopedic and neurosurgical medical device company with a meaningful orthobiologics portfolio (e.g., DBM, synthetics) targeting bone regeneration in similar trauma, spine and reconstructive indications to BONESUPPORT.
• SeaSpine (now part of SeaSpine Orthopedics): Spine-focused orthopedics and biologics company with a bone graft substitute portfolio directly comparable in product type and surgical use case to CERAMENT.
• Bioventus: Pure-play orthobiologics company selling bone graft substitutes and regenerative therapies to orthopedic surgeons — directly comparable product category, customer base (orthopedic surgeons/hospitals), and bone-healing focus.
• Orthofix Medical: Spine and orthopedic company selling bone growth stimulators and orthobiologics to the same trauma, spine and reconstructive surgeon customers as BONESUPPORT.

Others

• DSM Biomedical (dsm-firmenich): Materials supplier of bioceramic and polymer biomaterials to orthobiologics and medical device manufacturers; adjacent rather than competitive, but comparable in the underlying synthetic bone graft technology space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/cerament
• LinkedInlinkedin.com/company/bonesupport-ab

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries9 records

Funding overview

Funding rounds10 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BONESUPPORT